List of Katerzia drug patents

Katerzia is owned by Azurity.

Katerzia contains Amlodipine Benzoate.

Katerzia has a total of 8 drug patents out of which 0 drug patents have expired.

Katerzia was authorised for market use on 08 July, 2019.

Katerzia is available in suspension;oral dosage forms.

Katerzia can be used as angina pectoris; angina, a method of treating coronary artery disease; a method of treating hypertension, treatment of hypertension; method of treating hypertension.

The generics of Katerzia are possible to be released after 11 April, 2039.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11471409 AZURITY NA
Oct, 2037

(14 years from now)

US10959991 AZURITY Amlodipine formulations
Oct, 2037

(14 years from now)

US10894039 AZURITY Amlodipine formulations
Oct, 2037

(14 years from now)

US10952998 AZURITY Amlodipine formulations
Oct, 2037

(14 years from now)

US11484498 AZURITY NA
Oct, 2037

(14 years from now)

US11364230 AZURITY Amlodipine formulations
Oct, 2037

(14 years from now)

US10695329 AZURITY Amlodipine formulations
Oct, 2037

(14 years from now)

US10799453 AZURITY Amlodipine formulations
Apr, 2039

(16 years from now)

Drugs and Companies using AMLODIPINE BENZOATE ingredient

Market Authorisation Date: 08 July, 2019

Treatment: A method of treating coronary artery disease; A method of treating hypertension; Angina pectoris; Angina; Treatment of hypertension; Method of treating hypertension

Dosage: SUSPENSION;ORAL

How can I launch a generic of KATERZIA before it's patent expiration?
More Information on Dosage

KATERZIA family patents

14

United States

3

European Union

2

Canada

1

Japan

1

Spain

1

China

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in